Pharmaceutical

Smoking impairs immune response, even after quitting, n...

Experts have told us for decades that if you smoke, you should quit. And if you ...

HHS fills key vaccine advisory panel slots

HHS is filling eight vacancies on an important vaccine advisory panel after STAT...

Listen: Pharma goes to Washington, Alnylam’s future, & ...

This week on "The Readout LOUD" podcast": Has PhRMA lost its fangs? Are 11th-hou...

Covid-19 vaccine confidence soured by officials’ messag...

A House hearing on vaccine safety claims sought to pierce through Americans’ fal...

STAT+: FDA cracks down on websites that claim to sell c...

The FDA is cracking down on websites that claim to sell the underlying chemicals...

STAT+: Sick patients collapsed waiting for care at Mass...

Sick patients collapsed waiting for care in the overwhelmed emergency department...

FDA grants fast track status to Edgewise’s Duchenne tre...

The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506...

BioAge secures $170m for obesity therapeutics development

BioAge Labs has secured $170m in an Series D funding round to progress the devel...

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma

Ipsen reported that the US FDA approved the Onivyde regimen (NALIRIFOX) as a fir...

SCOPE: FDA facilitates AI and ML use for clinical trial...

Two FDA representatives FDA spoke at the ongoing 2024 SCOPE Summit about how the...

US lawmakers urge administration to take action against...

A bipartisan group of lawmakers is seeking an investigation and sanctions agains...

SCOPE: Changing protocol language and site actions are ...

A panel at the 2024 SCOPE Summit shared their experiences of setting up and runn...

FDA cracks down on online retailers selling unapproved ...

The FDA has issued warning letters to two online sellers for selling unapproved ...

BMS signs $674m GenAI drug discovery deal with VantAI

The partnership will focus on designing molecular glues for unspecified therapeu...

Grifols gears up for FDA approval of fibrinogen replace...

Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans ...

Sudo secures additional funds to advance TYK2 inhibitor...

Sudo Biosciences secured $30m in second round of Series B funding to further the...